Virpax Pharmaceuticals (VRPX) Competitors $0.68 +0.06 (+10.19%) (As of 02:20 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VRPX vs. NLSP, WENA, SNSE, AWH, TLPH, NKGN, TSBX, EGRX, CDT, and INDPShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include NLS Pharmaceutics (NLSP), ANEW Medical (WENA), Sensei Biotherapeutics (SNSE), Aspira Women's Health (AWH), Talphera (TLPH), NKGen Biotech (NKGN), Turnstone Biologics (TSBX), Eagle Pharmaceuticals (EGRX), Conduit Pharmaceuticals (CDT), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. NLS Pharmaceutics ANEW Medical Sensei Biotherapeutics Aspira Women's Health Talphera NKGen Biotech Turnstone Biologics Eagle Pharmaceuticals Conduit Pharmaceuticals Indaptus Therapeutics NLS Pharmaceutics (NASDAQ:NLSP) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Is NLSP or VRPX more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% Which has higher valuation & earnings, NLSP or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$12.17MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Does the MarketBeat Community prefer NLSP or VRPX? NLS Pharmaceutics received 5 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. However, 60.00% of users gave Virpax Pharmaceuticals an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Virpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% Do insiders and institutionals have more ownership in NLSP or VRPX? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 4.2% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend NLSP or VRPX? Virpax Pharmaceuticals has a consensus price target of $3.00, suggesting a potential upside of 341.24%. Given Virpax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, NLSP or VRPX? NLS Pharmaceutics has a beta of -0.51, meaning that its stock price is 151% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Does the media prefer NLSP or VRPX? In the previous week, Virpax Pharmaceuticals had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Virpax Pharmaceuticals and 1 mentions for NLS Pharmaceutics. Virpax Pharmaceuticals' average media sentiment score of 0.43 beat NLS Pharmaceutics' score of 0.20 indicating that Virpax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Virpax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVirpax Pharmaceuticals beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.33M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book-1.6210.276.976.37Net Income-$15.19M$153.22M$118.73M$225.56M7 Day Performance5.48%-1.19%-1.22%-0.02%1 Month Performance-5.78%-6.71%-3.07%2.04%1 Year Performance-89.05%32.39%32.52%28.00% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax Pharmaceuticals2.8979 of 5 stars$0.68+10.2%$3.00+341.2%-90.7%$3.33MN/A0.007Gap DownNLSPNLS Pharmaceutics1.2189 of 5 stars$3.31+0.6%N/A+623.1%$12.64MN/A0.006WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpSNSESensei Biotherapeutics4.8056 of 5 stars$0.48-2.8%$4.33+795.5%-20.0%$12.17MN/A0.0040News CoverageAWHAspira Women's Health1.6792 of 5 stars$0.74+1.4%$4.40+494.6%-78.5%$11.88M$9.15M-0.64110Analyst ForecastTLPHTalphera2.6915 of 5 stars$0.69-2.3%$4.50+552.1%N/A$11.75M$650,000.000.0019Gap UpNKGNNKGen BiotechN/A$0.33+5.8%N/A-89.1%$11.70M$80,000.00-0.06N/AGap UpHigh Trading VolumeTSBXTurnstone Biologics3.2023 of 5 stars$0.48+4.4%$2.13+342.7%-84.8%$11.10M$19.31M0.0082EGRXEagle Pharmaceuticals1.1175 of 5 stars$0.85+30.3%N/A-92.5%$11.04M$316.61M0.00134Analyst ForecastGap UpCDTConduit PharmaceuticalsN/A$0.11+22.0%N/A-92.8%$10.81MN/A0.003News CoverageGap UpHigh Trading VolumeINDPIndaptus Therapeutics2.7304 of 5 stars$1.05-1.4%$8.50+713.4%-48.7%$10.66MN/A0.006 Related Companies and Tools Related Companies NLSP Alternatives WENA Alternatives SNSE Alternatives AWH Alternatives TLPH Alternatives NKGN Alternatives TSBX Alternatives EGRX Alternatives CDT Alternatives INDP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRPX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRPX Stock Alerts